COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Phase I Study to Evaluate the Safety of Dexibuprofen 200mg Under Fasting and Fed Conditions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02956525
Recruitment Status : Unknown
Verified December 2017 by Apsen Farmaceutica S.A..
Recruitment status was:  Not yet recruiting
First Posted : November 6, 2016
Last Update Posted : December 14, 2017
Information provided by (Responsible Party):
Apsen Farmaceutica S.A.

Brief Summary:
Phase I Study to Evaluate the Safety of Dexibuprofen 200mg (Apsen Pharmaceuticals A / S.) After a Single and Multiple Dose Oral Administration in Healthy Participants of Both Sexes Under Fasting and Fed Conditions.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: Dexibuprofen Phase 1

Detailed Description:

A single oral dose of test medicine will be administered to participants in a practical period with the aid of 200 mL of water at room temperature. During administration, participants should stay in seated position. Participants will be confined at least 12 hours prior to administration and will remain for about 24 hours after the same, totaling about 36 hours of confinement.

After 36 hours of confinement the participantes will proceed to the multi-dose use phase for seven days in fed conditions.

To assess safety, an evaluation of the vital signs, laboratory tests and health status of the participants will be carried out throughout the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 52 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Phase I Clinical Study, Open-label, Randomized, Parallel to Evaluate the Safety of the 200 mg Dexibuprofen Following Single and Multiple Dose Oral Administration in Healthy Participants of Both Sexes Under Fasting and Fed Conditions.
Estimated Study Start Date : April 2018
Estimated Primary Completion Date : July 2018
Estimated Study Completion Date : July 2018

Arm Intervention/treatment
Experimental: Dexibuprofen 200 mg - Fed
Fed condition
Drug: Dexibuprofen
Dexibuprofen 200 mg

Experimental: Dexibuprofen 200 mg - Fasting
Fasting condition
Drug: Dexibuprofen
Dexibuprofen 200 mg

Primary Outcome Measures :
  1. To assess the safety of the drug through the incidence and classification of adverse events following single and multiple dose administration. [ Time Frame: 40 days ]
    Adverse events both recorded in the single-dose and multiple-dose

Secondary Outcome Measures :
  1. To evaluate the pharmacokinetics of the drug dexibuprofen at 200 mg concentration after single dose oral administration under fasting and fed conditions. [ Time Frame: 36 hours ]
    Evaluation of pharmacokinetic parameters: Tmax, Cmax, AUC, DV, Kel, CL and T1/2.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Participant able to understand and sign the informed consent of the study;
  • Healthy research participant, of both sexes, aged between 18 and 50 years, with BMI between 18.50 and 29.99 kg / m2;
  • Participant considered healthy by evaluating the medical history, vital signs and general clinical examination;
  • The results of clinical laboratory tests (biochemistry, hematology, serology, urinalysis and ECG certified by cardiologists) within the normal range established by the laboratory or changes that are considered not clinically significant by study physician.

Exclusion Criteria:

  • History of any major surgery in the last three months;
  • History present or previous history of any cardiac event, gastrointestinal, respiratory, hepatic, renal, endocrine, neurological, metabolic, psychiatric, hematologic, considered by the investigator as clinically significant and can endanger the participant's health;
  • History of chronic alcohol abuse, drugs, drugs and / or smoking in the last 6 months;
  • Known hypersensitivity to dexibuprofen, ibuprofen or its related (other nonsteroidal anti-inflammatory drugs) as well as components present in the formulation;
  • History of use of drugs that potentially interfere with the kinetics / dynamics dexibuprofen or any other medication considered clinically significant by the investigator with time less than 7 times of drug half-life preceding the period of inclusion;
  • Regular consumption of grapefruit and / or their derivatives;
  • Pregnant women and nursing mothers;
  • Donation or loss of 450 ml or more of blood within 3 months before the study and / or hospitalization for any reason, up to 4 weeks before the beginning of it.
  • Participation in any clinical trial in the last 12 months preceding the start of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02956525

Layout table for location contacts
Contact: Fernanda Martinez, B.Sc.(Pharm) + 55 11 5644-8200 ext 8404

Layout table for location information
Azidus laboratories Ltd.
Valinhos, São Paulo, Brazil, 13271-130
Sponsors and Collaborators
Apsen Farmaceutica S.A.
Layout table for investigator information
Principal Investigator: Dra. Regina Mayumi Doi, MD Azidus
Layout table for additonal information
Responsible Party: Apsen Farmaceutica S.A. Identifier: NCT02956525    
Other Study ID Numbers: DEXAPS0716OR-LD
First Posted: November 6, 2016    Key Record Dates
Last Update Posted: December 14, 2017
Last Verified: December 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No